SMAD4 and neoplasm: SMAD4 showed a low positivity in 9 (36%) cases (Figure 5), with 60–80% of the tumor cells exhibiting immunoreactivity and the other additional 11 (44%) cases showed a high positivity (Figure 2) with 40–90% of the tumor cells exhibiting immunoreactivity.